
PathAI
Pathology & Laboratory Diagnostics
PathAI improves patient outcomes with AI-powered pathology technology, offering insights for biomarker discovery, drug development, and enhanced laboratory workflows.
About PathAI
PathAI is dedicated to improving patient outcomes with reliable AI-powered technology and meaningful collaboration with biopharma and pathology laboratories.
Mission & Approach
Mission
“Our Mission is to Improve Patient Outcomes with AI-Powered Pathology”
AI Approach
computer vision, deep learning, graph neural networks, generative AI for histopathology image analysis and biomarker quantification
Product & Market
Product Stage
enterprisePrimary Market
pharmaCompany Details
- Founded
- 2016
- Headquarters
- Boston, MA, USA
- Employees
- 750
- Stage
- acquired
- Profile last updated
- June 22, 2026
Official Sources
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSocial & Media
Follow on
X / Twitter
View Profile →Latest Updates

PathAI’s AISight® Dx IMS Platform Supports the AISight Consults Workflow for Streamlined Digital Consult Management
PathAI’s AISight® Dx IMS platform supports digital consult workflow capabilities through the AISight Consults workflow, helping institutions manage pathology consults, second opinions, and referrals more efficiently while moving beyond fragmented processes often dependent on glass slide shipment, manual coordination, and disconnected communication. By supporting digital case submission, review, collaboration, and reporting within a unified IMS experience, AISight Dx can help reduce turnaround ti
May 14, 2026
Read more →
PathAI Advances AISight® Dx with the v2.20 Release: Enhancing Viewer Usability, Workflow Efficiency, and Platform Reliability
We're thrilled to announce the release of AISight® Dx v2.20, the latest update to PathAI's FDA-cleared digital pathology image management system. At PathAI, every release is driven by one goal: making digital pathology work better for the people who depend on it every day. This update reflects direct feedback from our users and our ongoing commitment to removing friction from clinical workflows, so pathologists and lab teams can stay focused on what matters most.
May 11, 2026
Read more →
PathAI and A.C.Camargo Cancer Center announce cooperation to expand digital pathology with AI in Brazil via SUS
Boston, MA and São Paulo, Brazil – May 5th, 2026 – PathAI, a global leader in AI-powered digital pathology solutions, and A.C.Camargo Cancer Center, a national benchmark in oncological treatment, education, and research, are joining forces strategically to support the adoption of digital and AI-enabled pathology across Brazil. The collaboration reinforces the country's national efforts to modernize oncological diagnostics and strengthens PathAI's growing presence in the region.
May 5, 2026
Read more →
PathAI and MedStar Health Announce Partnership to Deploy the AISight® Dx Digital Pathology Platform and Advanced AI Applications
BOSTON, MA, and COLUMBIA, MD – April 7, 2 026 - PathAI, a leading provider of AI-powered pathology solutions, and MedStar Health, a leading health system headquartered in Columbia, Maryland, today announced a multi-year strategic collaboration to deploy PathAI’s AISight® Dx 1 Digital Pathology Platform and various AI algorithm products across the multi-site network.
Apr 7, 2026
Read more →
PathAI Expands AISight® Dx with the v2.19 Release: Enhancing Flexibility, Collaboration, Reporting and Workflow Precision
PathAI Expands AISight® Dx with the v2.19 Release: Enhancing Flexibility, Collaboration, Reporting and Workflow Precision
Mar 11, 2026
Read more →PathAI in the News
All News →Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.
